Eplerenone for Chronic Central Serous Chorioretinopathy in Patients with Active, Previously Untreated Disease for more than 4 Months (VICI): A Randomised, Double-blind, Placebo-controlled TrialThe VICI trial is highly topical. Dr Narme Deva, Consultant Ophthalmologist & Honorary Senior Lecturer at the University of Auckland, explores the Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. She explains the results are unequivocal and based on a robust trial of 114 patients. Eplerenone does not improve BCVA in people with chronic CSCR after 12 months of treatment. As ever, Dr Deva reminds listeners that evidence-based medicine includes using reliable data to make decisions, even when patients and ophthalmologists are faced with limited treatment options to prevent vision loss.View article here

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related